Verastem (VSTM) Gains from Sales and Divestitures (2012 - 2026)
Verastem (VSTM) recorded quarterly Gains from Sales and Divestitures of $271875.0 in Q1 2026, down 42.02% quarter-over-quarter from $468885.0 in Q4 2025, and up 137.77% on a YoY basis from $114342.0 in Q1 2025.
Verastem (VSTM) Gains from Sales and Divestitures (2012 - 2026) Analysis & Trends
Verastem's Gains from Sales and Divestitures history runs 13 years deep, the most recent figure standing at $271875.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures rose 137.77% year-over-year to $271875.0; the TTM figure through Mar 2026 stood at $271875.0 (up 137.77% YoY), while the FY2025 annual figure was $468885.0, up 171.51% from the prior year.
- Gains from Sales and Divestitures was $271875.0 for Q1 2026 at Verastem, down from $468885.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $642000.0 in Q3 2025 to a low of $14279.0 in Q1 2024.
- Historically, Gains from Sales and Divestitures has averaged $245374.1 across 5 years, with a median of $172697.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures plunged 93.76% in 2024, then surged 1665.78% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $541012.0 in 2022, then plunged by 85.15% to $80367.0 in 2023, then soared by 114.89% to $172697.0 in 2024, then surged by 171.51% to $468885.0 in 2025, then slumped by 42.02% to $271875.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $271875.0 (Q1 2026), $468885.0 (Q4 2025), and $642000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 271,875.00 |
| Mar 31, 2026 | 271,875.00 |
| Dec 31, 2025 | 468,885.00 |
| Dec 31, 2025 | 468,885.00 |
| Sep 30, 2025 | 642,000.00 |
| Sep 30, 2025 | 642,000.00 |
| Jun 30, 2025 | 591,731.00 |
| Jun 30, 2025 | 591,731.00 |
| Mar 31, 2025 | 114,342.00 |
| Mar 31, 2025 | 114,342.00 |
| Dec 31, 2024 | 172,697.00 |
| Dec 31, 2024 | 172,697.00 |
| Sep 30, 2024 | 78,657.00 |
| Sep 30, 2024 | 78,657.00 |
| Jun 30, 2024 | 33,511.00 |
| Jun 30, 2024 | 33,511.00 |
| Mar 31, 2024 | 14,279.00 |
| Mar 31, 2024 | 14,279.00 |
| Dec 31, 2023 | 80,367.00 |
| Dec 31, 2023 | 80,367.00 |